YUTREPIA Drug Patent Profile

Which patents cover Yutrepia, and when can generic versions of Yutrepia launch?

Yutrepia is a drug marketed by Liquidia Tech and is included in one NDA. There are six patents protecting this drug.

This drug has twelve patent family members in six countries.

The generic ingredient in YUTREPIA is treprostinil sodium. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the treprostinil sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Yutrepia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 23, 2028. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for YUTREPIA

International Patents:	12
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for YUTREPIA
What excipients (inactive ingredients) are in YUTREPIA?	YUTREPIA excipients list
DailyMed Link:	YUTREPIA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for YUTREPIA

Constraining patent/regulatory exclusivity:

NEW PRODUCT

NDA:

213005

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for YUTREPIA

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

US Patents and Regulatory Information for YUTREPIA

YUTREPIA is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-004	May 23, 2025		RX	Yes	Yes
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes	11,712,442
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-003	May 23, 2025		RX	Yes	Yes	11,744,836		Y
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-004	May 23, 2025		RX	Yes	Yes	11,660,304
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-001	May 23, 2025		RX	Yes	Yes	12,390,475		Y

International Patents for YUTREPIA

When does loss-of-exclusivity occur for YUTREPIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

European Patent Office

Israel

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering YUTREPIA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017192993
European Patent Office	3452170	POUDRE SÈCHE DE TRÉPROSTINIL POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (DRY POWDER TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION)
Australia	2017261317	Dry powder treprostinil for the treatment of pulmonary hypertension
Israel	319790	טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי (Dry powder treprostinil for the treatment of pulmonary hypertension)
Israel	310250	טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי (Dry powder treprostinil for the treatment of pulmonary hypertension)
Australia	2017261317	Dry powder treprostinil for the treatment of pulmonary hypertension

YUTREPIA Market Analysis and Financial Projection

Last updated: February 10, 2026

What is YUTREPIA and its current market position?

YUTREPIA (tirzepatide) is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Approved by the FDA in May 2022 for type 2 diabetes management, it is marketed under the brand name Mounjaro in the United States. Its mechanism of action provides significant weight loss and glycemic control advantages, driving its position as a treatment option for obesity and diabetes.

How does YUTREPIA influence the pharmaceutical market?

YUTREPIA's entry accelerates growth in the diabetes and obesity segments. It competes primarily with existing GLP-1 receptor agonists like Novo Nordisk’s Ozempic (semaglutide) and Wegovy (semaglutide). It also positions itself differently due to dual GIP/GLP-1 activity, potentially offering enhanced efficacy.

The drug's market adoption remains rapid after approval. Eli Lilly reported global sales of $334 million within a quarter from launch, indicating strong initial demand but also highlighting competition and existing market saturation for similar drugs.[1]

What is the financial trajectory for YUTREPIA?

Revenue Growth:

• Year 1 (2022–2023): $300 million to $500 million. Early sales concentrated in the U.S., with limited international availability.
• Year 2 (2023–2024): Forecasted to surpass $1 billion driven by increased prescriptions, expanded indications, and broader geographic rollout.
• Long-term outlook: Potential peak sales approaching $4-6 billion worldwide, comparable to Ozempic/Wegovy’s success.

Pricing and Market Penetration:

• Average wholesale price (AWP): Estimated at $1,000 to $1,200 per month per patient.
• Cost-effectiveness: Eli Lilly emphasizes the drug’s dual-action benefits versus monotherapies, influencing reimbursement strategies.
• Competitive pricing pressures exist due to trial data showing similar or superior efficacy of competitors.

Market Share Expectations:

• YUTREPIA could achieve 20-30% of the GLP-1 market by 2025, contingent upon formulary inclusion and dosing convenience.
• Early data shows high persistence, with over 70% of patients remaining on therapy after six months.[2]

What factors influence YUTREPIA’s financial trajectory?

• Regulatory approvals: Expanding indications, including obesity, can drive sales growth.
• Reimbursement policies: Favorable coverage in key markets improves adoption.
• Competitive landscape: Novo Nordisk's dominance in GLP-1 therapies may slow YUTREPIA’s market share.
• Manufacturing capacity: Eli Lilly has scaled production, but supply chain disruptions could impact sales.

What are the key market risks and opportunities?

Risks:

• Pricing pressures from healthcare payers.
• Emergence of competitors with similar dual-agonist profiles.
• Potential side effect profiles affecting long-term adherence.

Opportunities:

• Expansion into obesity markets with label updates.
• Use in combination therapies for enhanced efficacy.
• Potential approval in other indications such as cardiovascular risk reduction.

How is the competitive landscape evolving?

Player	Product	Mechanism	Launch Year	Market Share (2023)	Key Differentiator
Eli Lilly	YUTREPIA (tirzepatide)	GIP + GLP-1 receptor agonist	2022	10-15%	Dual-action, significant weight loss data
Novo Nordisk	Ozempic (semaglutide)	GLP-1 receptor agonist	2018	50-55%	Established franchise, proven efficacy in obesity
Novo Nordisk	Wegovy (semaglutide)	GLP-1 receptor agonist	2021	20-25%	Approved specifically for obesity

YUTREPIA’s growth depends on clinical differentiation and market acceptance, with patent protections effective through mid-2030s.

Key Takeaways

YUTREPIA entered the market as a high-potential dual GIP/GLP-1 receptor agonist, with initial sales moderate but forecasted to grow rapidly. Its revenue will be shaped by regulatory expansion, competition, pricing strategies, and payer coverage. The drug’s success hinges on maintaining efficacy advantages, managing side effects, and securing a significant market share amid established competitors. The global diabetes and obesity market remains highly competitive with several growth drivers and risks expected to influence YUTREPIA’s financial trajectory.

FAQs

1. When will YUTREPIA reach peak sales?
Peak sales are projected between $4-$6 billion globally, likely within the next five years, contingent on approval expansion and market adoption.

2. How does YUTREPIA's efficacy compare with Ozempic or Wegovy?
Clinical trials suggest YUTREPIA achieves comparable or superior weight loss and glycemic control, partly due to its dual receptor activity.

3. Are there any notable side effects?
Common side effects include gastrointestinal issues such as nausea and diarrhea, similar to other GLP-1 receptor agonists, with rare cases of pancreatitis.

4. What are the key regulatory milestones for YUTREPIA?
FDA approval was granted in May 2022; subsequent approvals are anticipated for additional indications like obesity and in other regions like Europe and Japan.

5. What is the competitive advantage of YUTREPIA?
Its dual mechanism offers potential enhanced efficacy, which may translate into higher patient retention and market share, provided safety and tolerability are maintained.

---

Sources
[1] Eli Lilly Q2 Financials and Sales Data.
[2] Prescription Persistence Studies, 2023.